对于高血压、T2D、慢性肾脏病或动脉粥样硬化性心血管疾病患者，SGLT2 抑制剂可降低高血压住院率和心血管疾病死亡率。

IF 19.6 1区医学 Q1 MEDICINE, GENERAL & INTERNAL

Annals of Internal Medicine Pub Date : 2024-11-01 Epub Date: 2024-11-05 DOI:10.7326/ANNALS-24-02459-JC

Doreen Zhu, William G Herrington

引用次数: 0

摘要

来源引用：Usman MS, Bhatt DL, Hameed I, et al. SGLT2 抑制剂对心血管代谢疾病谱中心衰结局和心血管死亡的影响：系统综述和荟萃分析。Lancet Diabetes Endocrinol.2024;12:447-461.38768620.

本文章由计算机程序翻译，如有差异，请以英文原文为准。

查看原文本刊更多论文

In HF, T2D, CKD, or atherosclerotic CVD, SGLT2 inhibitors reduce HF hospitalizations and CV mortality.

Source citation: Usman MS, Bhatt DL, Hameed I, et al. Effect of SGLT2 inhibitors on heart failure outcomes and cardiovascular death across the cardiometabolic disease spectrum: a systematic review and meta-analysis. Lancet Diabetes Endocrinol. 2024;12:447-461. 38768620.

求助全文

通过发布文献求助，成功后即可免费获取论文全文。去求助

来源期刊

Annals of Internal Medicine 医学-医学：内科

CiteScore

23.90

自引率

1.80%

发文量

1136

审稿时长

3-8 weeks

期刊介绍： Established in 1927 by the American College of Physicians (ACP), Annals of Internal Medicine is the premier internal medicine journal. Annals of Internal Medicine’s mission is to promote excellence in medicine, enable physicians and other health care professionals to be well informed members of the medical community and society, advance standards in the conduct and reporting of medical research, and contribute to improving the health of people worldwide. To achieve this mission, the journal publishes a wide variety of original research, review articles, practice guidelines, and commentary relevant to clinical practice, health care delivery, public health, health care policy, medical education, ethics, and research methodology. In addition, the journal publishes personal narratives that convey the feeling and the art of medicine.